

Cochrane group skeptical about latest Roche pledges

March 7 2013



Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in *BMJ*.

(HealthDay)—Following requests from Cochrane researchers, Roche has pledged to release full clinical study reports for Tamiflu, although there appear to be conditions attached, according to correspondence published in *BMJ*.

Peter Doshi, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, along with colleagues from the Cochrane group, recently corresponded with Roche as part of the BMJ's open data campaign designed to encourage Roche to honor its 2009 commitment to make the full clinical study reports for 10 trials of Tamiflu available for independent review.

Noting that Roche recently pledged to release full clinical study reports as part of the data transparency program, the authors question these new



promises. Roche plans to allow researchers access to a secure system, following agreement, rather than the requested independent review. Three of the four advisors chosen to lead Roche's advisory board, which will grant access to data, have recent financial ties to Roche. In addition, there has been no attempt to correct the scientific record following the 2003 Roche-authored paper claiming the opposite of the U.S. Food and Drug Administration conclusion that Tamiflu has not been shown to prevent serious bacterial complications of influenza.

"Despite our repeated requests for those data, <u>Roche</u> has yet to provide even a single full study report," Doshi writes. "We are independent scientists, not regulators. Doing our own analysis, not dictated by others, is key to what makes us independent."

More information: More Information

Health News Copyright © 2013 HealthDay. All rights reserved.

Citation: Cochrane group skeptical about latest Roche pledges (2013, March 7) retrieved 26 April 2024 from

https://medicalxpress.com/news/2013-03-cochrane-group-skeptical-latest-roche.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.